Company profile: Apceth Biopharma
1.1 - Company Overview
Company description
- Provider of GMP-compliant contract development and manufacturing services for complex cell and gene therapy products (ATMPs). Services include GMP manufacturing for clinical and commercial therapies, process development and optimization, analytical testing and quality control, cell therapy consulting, QP batch certification and EU import, supported by GMP facilities across North America, Europe, and Asia.
Products and services
- GMP Manufacturing: Delivers GMP-compliant production for clinical and commercial cell and gene therapy products (ATMPs), executing manufacturing operations under regulated standards and compliant oversight
- Manufacturing Development: Engineers process development for cell and gene therapies, including scale-up and optimization to refine manufacturing workflows and increase readiness for larger clinical or commercial production
- QP Batch Certification: Supplies Qualified Person (QP) batch certification and EU import services for cell and gene therapy products manufactured outside the European Union, ensuring compliant market release
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Apceth Biopharma
Lindis Blood Care
HQ: Germany
Website
- Description: Provider of a medical device for removing cancer cells from intraoperative blood during cancer surgeries to enable autologous blood transfusion (CATUVAB), and a multicenter clinical certification study (REMOVE) assessing the device’s efficacy and safety in tumor cell removal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lindis Blood Care company profile →
Chinook Therapeutics
HQ: Canada
Website
- Description: Provider of precision medicines for kidney diseases, leveraging novel translational platforms and patient stratification tools. Pipeline includes Atrasentan, a selective ETA receptor antagonist in phase 3 for IgA nephropathy and phase 2 for other proteinuric glomerular diseases; Zigakibart (BION-1301), an anti-APRIL monoclonal antibody in phase 3 and phase 1/2 for IgA nephropathy; and CHK-336, an oral LDHA inhibitor in phase 1 for primary and idiopathic hyperoxaluria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chinook Therapeutics company profile →
2seventy bio
HQ: United States
Website
- Description: Provider of immuno-oncology cell therapies, discovering and developing cancer treatments, including ABECMA (idecabtagene vicleucel), a CAR T cell therapy for multiple myeloma developed in collaboration with Bristol Myers Squibb; leveraging expertise in cancer cell biology, genetics, and the immune response to advance its pipeline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 2seventy bio company profile →
Dendreon
HQ: United States
Website
- Description: Provider of immunotherapy and cell therapy services, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for advanced prostate cancer; end-to-end cell therapy manufacturing; patient operations and logistics to deliver treatments within an 18-hour window across the U.S.; process and analytical development; and cGMP quality assurance and quality control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dendreon company profile →
Molecular Insight
HQ: United States
Website
- Description: Provider of biopharmaceutical innovations in molecular medicine, applying molecular-level disease identification and targeting to improve patient healthcare and address significant unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Insight company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Apceth Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Apceth Biopharma
2.2 - Growth funds investing in similar companies to Apceth Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Apceth Biopharma
4.2 - Public trading comparable groups for Apceth Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →